The patient's perspective is important to fully understand the impact of glaucoma and its treatment on functioning and well-being, and should be included in research evaluations because treatment effects experienced by the patient may not be detected by health care providers. Disease-targeted health-related quality of life (HRQoL) instruments are more sensitive to small changes in specific conditions and may help assess clinical outcomes of glaucomatous disease as well as the effects of treatment. The UCSF-Stanford Center of Excellence in Regulatory Science and Innovation , the American Glaucoma Society, and FDA Center for Devices and Radiological Health have developed a HRQoL instrument, the Glaucoma Outcomes Survey (GOS), targeted for glaucoma patients who undergo minimally invasive glaucoma surgery (MIGS). The objective of this study is to assess the reliability and validity of the GOS in a sample of glaucoma patients who undergo MIGS with cataract surgery. Ultimately, the instrument can be used more broadly as a research tool to assess the impact of surgical intervention on patients in medical studies and in clinical practice to improve quality of care.
Open and enrolling
Investigator: Sylvia Sudat, PhD
Investigator: Su-Ying Liang, Ph.D.
Investigator: Kristen M.J. Azar, R.N., BSN, MSN/MPH